DBV Technologies S.A. 8K

DBV Technologies reported increased losses and higher R&D and commercial preparation spending for the first half of 2026 while advancing its VIASKIN Peanut Patch BLA toward an expected third quarter 2026 submission and confirming cash runway into the third quarter of 2027.

DBV Technologies filed a Form 8-K to furnish its second quarter and half-year 2026 financial results and business update, highlighting continued progress toward a planned third quarter 2026 submission of its BLA for the VIASKIN Peanut Patch in children aged 4–7, closure of recruitment in the COMFORT Toddlers safety study, initiation of the THRIVE study in infants, and active scientific engagement. The company reported a net loss of $98.0 million for the six months ended June 30, 2026 (including $50.4 million for Q2), driven by increased R&D and SG&A expenses related to clinical trial activity, BLA preparation, U.S. commercial build-out, and pre-commercial inventory for a potential U.S. launch of VIASKIN Peanut Patch, partially offset by modest operating income and improved net financial income. As of June 30, 2026, DBV held $174.9 million in cash and cash equivalents, and management believes this provides funding into the third quarter of 2027 based on current plans focused primarily on VIASKIN Peanut Patch, while cautioning that actual cash needs could differ and that additional capital may be sought to support long-term strategy. The report also notes inclusion of DBV in key European equity indices, an unchanged epidemiologic prevalence of peanut allergy despite earlier allergen introduction practices, and announces a same-day investor call and webcast to discuss the results.

Filing Facts

CIK

1613780

Ticker

DBVT

Form

8K

Source Type

fda

Accession

0001193125-26-306222

Alert Tier

6